Improving Profit Margins Through Cost Reduction and Streamlining
First written in FY2023-Q2. 6 of 10 entries say "Advanced", first in FY2023-Q3. Latest entry: FY2026.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Operating profit in Diabetes Management was ¥20,085 million, up 44.6% year on year.」
Improved unit prices and profitability, cost reductions from structural reforms, lower depreciation and amortization expenses, and other factors were reflected in higher full-year operating profit in Diabetes Management. - 2026-05-13AdvancedEarnings
「The LSIM business increased profit as a result of higher revenue and cost reductions.」
In the LSIM business, higher testing revenue in the genetics field and cost reductions were reflected in higher revenue and profit. - FY2026-H1AdvancedAnnual report
「Operating profit in Diabetes Management was ¥9,328 million, up 46.6% year on year. Although the review of head-office functions described above had a negative impact of ¥143 million, earnings increased significantly due to strong performance by the BGM business in developed markets, improved margins from profitability-improvement and unit-price enhancement measures, the benefits of cost reductions from past structural reforms, and lower depreciation and amortization expenses.」
Profitability improvements, higher unit prices and cost reductions from past structural reforms in the BGM business drove a 46.6% year-on-year increase in operating profit in Diabetes Management. - FY2025AdvancedAnnual report
「Operating profit in Healthcare Solutions was ¥9,272 million, compared with an operating loss of ¥9,446 million in the same period of the previous year. This was mainly because the impact of the ¥12,737 million impairment loss recognized by the LSIM business in the third quarter of the previous fiscal year was absent in the current period, in addition to a significant increase in earnings from cost reductions and other factors.」
The absence of the LSIM business's impairment impact and cost reductions and other factors turned Healthcare Solutions from an operating loss into operating profit of ¥9,272 million. - FY2025-H1AdvancedAnnual report
「Operating profit in Healthcare Solutions was ¥3,635 million, up 282.2% year on year. This was mainly due to higher earnings in the LSIM business from cost reductions and other factors, as well as improved margins in the Healthcare IT Solutions business. The latter continued to be affected by lower demand for the online eligibility-verification system, higher purchase prices for IT equipment and increased personnel expenses, but margins improved as sales of the higher-margin electronic prescription management software increased.」
Cost reductions in the LSIM business and higher sales of electronic prescription management software drove a 282.2% year-on-year increase in operating profit in Healthcare Solutions, providing quantitative evidence of margin improvement. - FY2024RestatedAnnual report
「The pathology business posted higher earnings, owing to a year-on-year decrease in impairment losses, the benefits of profitability-improvement initiatives and a gain on the sale of shares in an affiliated company recognized in the second quarter of the current fiscal year.」
Although the company continued to report the benefits of profitability-improvement initiatives in the pathology business, price increases and cost reductions alone were insufficient to close the gap with the business plan, and an impairment loss was also recognized. - FY2024-Q3RestatedAnnual report
「In the pathology business, the main factor was a ¥2,113 million impairment loss on goodwill recognized in the second quarter of the current fiscal year, despite the benefits of initiatives to improve profitability and a gain on the sale of shares in an affiliated company recognized during the same period.」
The company continued to report the benefits of profitability-improvement initiatives in the pathology business, but operating profit declined 21.3% year on year due to impairment losses on goodwill and other factors. - FY2024-Q2RestatedAnnual report
「Although measures including price increases and cost reductions have produced some improvement in performance, a gap has emerged between actual performance and the business plan.」
While highlighting the benefits of cost reductions and streamlining, the company explained that a gap had emerged between the pathology business and its business plan. - FY2023-Q3AdvancedAnnual report
「Operating profit in Diagnostics and Life Sciences was ¥6,258 million, up 36.5% year on year. Although the business was affected by the Shanghai lockdown in the first quarter, higher selling, general and administrative expenses and increased costs associated with M&A, it significantly increased earnings as the impact of higher raw-material and transportation costs was mitigated through cost-reduction initiatives and passing those increases through to product prices, together with the revenue growth described above.」
The impact of higher raw-material and transportation costs was mitigated through cost reductions, streamlining and passing the increases through to product prices, resulting in a 36.5% year-on-year increase in operating profit in Diagnostics and Life Sciences. - FY2023-Q2First statedAnnual report
「Although the benefits of cost reductions and streamlining that contributed to higher margins were evident, the main factors were the impact of lower revenue from COVID-19 PCR testing, higher selling, general and administrative expenses accompanying revenue growth in the Medicom business, and the incurrence of temporary business-structure-reform costs.」
The company stated that the benefits of cost reductions and streamlining were emerging in Healthcare Solutions, while lower PCR testing revenue and higher selling expenses were factors behind the decline in earnings.